

CONTACTS

Christian Rohlf, Chief Executive Officer

ADDRESS

The Forum
86 Milton Park
Abingdon OX14 4RY
UK

TELEPHONE

+44 (0) 1235 86 1770

FAX

+44 (0) 1235 86 1771

EMAIL

Christian.Rohlf@OxfordGenomeSciences.com

HISTORY

Founded in 2004.

FINANCIAL SUMMARY

Funding has been provided by Southeast Growth Fund, Oxford Capital Partners and Catapult Venture Managers Ltd.

MANAGEMENT

Christian Rohlf, Chief Executive Officer

Mike Gresser, Chief Scientific Officer

Gron Ffoulkes-Davies, Head of Finance

Martin Barnes, Head of Bioinformatics

Alasdair Stamps, Head of Target
Discovery

David Bell, Head of Mass Spec
Operations

Ben Reed, Business Development
Director of the Biomarker Services
division

COMPANY PROFILE

Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex Inc. and Biosite (now part of Inverness Medical Innovations Inc.) to build a broad pipeline of novel antibody therapeutics using its unique OGAP[®] (Oxford Genome Anatomy Project) platform, one of the world's largest human protein databases. OGeS also intends to develop companion diagnostics for each of its antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into drug development and product commercialisation activities.

Strategy

OGeS' strategy is to use its unique and integrated OGAP[®] discovery platform in alliances with the world's leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics. This approach is expected to deliver innovative and cost-effective medicines to fulfill unmet patient needs in the field of cancer. In parallel, OGeS provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies providing OGeS with short-term revenues.

OGAP[®] INTEGRATION PLATFORM

OGAP[®] (Oxford Genome Anatomy Project) is the world's largest proteomic / genomic data integration system and is core to Oxford Genome Sciences' approach to delivering personalised therapeutic solutions.

The OGAP[®] system integrates all clinical, experimental information and experimental expression data from:

- ~1 million human protein peptide sequences
- ~15,000 "confirmed" genes
- ~ 50 tissues/organs
- ~ 58 diseases
- ~ 8 million SNPs and haplotypes
- Built-in comparative gene mapping from relevant preclinical models

Applications

- Target discovery & validation
- Identification of biomarkers for drug development
- Development of companion diagnostics for personalised medicine
- Target re-profiling

COLLABORATIONS

A landmark three-way agreement between OGeS, Medarex and Biosite to accelerate the development of OGeS' own pipeline of antibody therapeutics in cancer. Under this unique agreement Biosite will carry out the early stage antibody generation on behalf of OGeS using Medarex's proprietary transgenic mouse technology under a license agreement.



A strategic collaboration with Medarex to co-discover, co-develop and co-commercialise new human antibody therapeutics for the treatment of cancers including colorectal cancer (CRC), on a **50:50 cost and profit share basis**.



A partnership that covers the development of novel **blood-based diagnostics** for the early screening of colorectal and ovarian cancers. OGeS will identify and evaluate a set of biomarkers, for which Biosite has the rights to develop diagnostic tests. OGeS will receive research milestone payments, royalties and retains high-throughput screening (HTS) rights.

PRODUCT PIPELINES

OGeS has developed a broad pipeline of both therapeutic antibodies and diagnostics in the field of cancer based on its strategic collaborations with Medarex and Biosite.

Therapeutic Antibody Pipeline

OGeS' most advanced therapeutic antibody programmes are developed in collaboration with Medarex on a 50:50 cost and profit share basis. The lead programmes are targeting a number of solid cancer indications including colorectal cancer and are expected to produce several clinical development candidates in 2008. OGeS is developing a companion diagnostic for several of these programmes in collaboration with Biosite.

OGeS has obtained broad access to Medarex's fully human antibody technology with the aim of accelerating the development of its own pipeline of novel antibodies in the field of cancer. Under the terms of the agreement, OGeS will retain full worldwide rights to the antibodies. In parallel, to further accelerate its pipeline development, OGeS has established a three-way agreement with Biosite and Medarex. Medarex will provide access to its transgenic technology to Biosite, and Biosite will carry out the early stage antibody generation on behalf of OGeS for a potentially large number of OGeS' antibody programmes. This is partly in exchange for Biosite receiving access to the OGeS diagnostic targets in colorectal and ovarian cancer. This arrangement is expected to improve OGeS' productivity to put top quality antibody therapeutic programmes into development more quickly.

OGeS has identified a number of cancer targets from its OGAP[®] database, five of which are now being prepared to enter the preclinical development phase and OGeS has identified another 15 targets that will also be committed into the same pipeline.

In addition, under a separate agreement between OGeS and Biosite, Biosite can also establish a companion diagnostic assay on certain programmes selected by Biosite and OGeS. This provides OGeS with the opportunity to create a significant portfolio of personalised cancer therapeutics with companion diagnostics for many of its oncology targets.

Diagnostic Pipeline

OGeS in collaboration with Biosite has built a promising pipeline of blood-based cancer diagnostics for the diagnosis and prognosis of colorectal and ovarian cancer. Under the terms of the collaboration, novel diagnostic markers identified by OGeS through OGAP[®] will be developed by Biosite into blood-based diagnostic products. OGeS will receive research milestone payments and royalties. The most advanced diagnostic programme is for colorectal cancer and is currently in clinical evaluation. OGeS and Biosite initiated a second diagnostic programme for ovarian cancer in 2007.